Homoharringtonine: all 42 studies that test it

Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureEnrolling by invitationNCT07813390Phase 2
• Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationNCT07651176Phase 2/3
• Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationNCT07651163Phase 2/3
• Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical StudyNot yet recruitingNCT07516704Early Phase 1
• Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML PatientsNot yet recruitingNCT07505160Phase 2
• VAH vs VA in Newly Diagnosed Elderly AMLNot yet recruitingNCT07469046Phase 3
• Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical StudyRecruitingNCT07163910Phase 2
• Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07159906Phase 1/2
• MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
• Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingNCT06855810Phase 2/3
• Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNCT06529250Not applicable
• Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.RecruitingNCT06483906Phase 2
• Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLRecruitingNCT06361329Phase 3
• Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
• Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingNCT06221683Phase 2
• Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingNCT05805098Phase 2/3
• Omacetaxine + Azacitidine in Untreated Patients With High Grade MDSActive, not recruitingNCT03564873Phase 1/2Results posted
• Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) FailureCompletedNCT02159872Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)TerminatedNCT02078960Phase 1/2Results posted
• Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02029417Phase 2Results posted
• Omacetaxine for Consolidation and MaintenanceTerminatedNCT01873495Phase 2Results posted
• Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01272245Phase 2Results posted
• Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CMLCompletedNCT00462943Phase 2Results posted
• Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene MutationCompletedNCT00375219Phase 2Results posted
• Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)TerminatedNCT00114959Phase 2Results posted
• HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AMLActive, not recruitingNCT06744556Phase 2
• Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid LeukemiaCompletedNCT05906914Phase 2
• Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)CompletedNCT04926285Phase 1
• Azacitidine and Homoharringtonine in JMMLStatus unknownNCT04505995Not applicable
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
• Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITDCompletedNCT03170895Phase 2
• Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITDStatus unknownNCT03135054Phase 2
• A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)WithdrawnNCT02835794Phase 1/2
• Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02141477Phase 1
• An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine MepesuccinateCompletedNCT01844869Phase 1
• Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic TumorsCompletedNCT00675350Phase 1
• Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic LeukemiaWithdrawnNCT00030355Phase 1/2
• Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00006364Phase 2
• Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaTerminatedNCT00004933Phase 3
• Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT00003694Phase 2
• Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00003239Phase 2
• Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002574Phase 2

← Homoharringtonine overview